Mometasone
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Atectura Breezhaler | — | 2020-05-30 | europa.eu ↗ |
Trials 33 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03979209 | Jan 2019 → Jun 2021 | chronic rhinosinusitis | Rush University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02154334 | Jun → Oct 2014 | allergic rhinitis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01061333 | Jun 2010 → Feb 2011 | asthma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT05756647 | Nov 2022 → Jul 2023 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03444506 | Jan → Feb 2014 | seasonal allergic rhinitis | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 2 | NCT01636076 | Nov 2012 → Sep 2013 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01258803 | Dec 2010 → Oct 2011 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 2 | NCT01119313 | Feb → Mar 2010 | atopic eczema | Almirall, S.A. | Completed | No outcome recorded |
| Phase 2 | NCT00605306 | Jan → Apr 2008 | asthma | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00557440 | Nov 2007 → Apr 2008 | asthma | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00556673 | Oct 2007 → Apr 2008 | asthma | Novartis | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT05776927 | May 2026 → Dec 2028 expected | asthma | Novartis Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05562466 | May 2023 → Feb 2028 expected | asthma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT05311475 | Apr 2022 → Jun 2023 | seasonal allergic rhinitis | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT04206761 | Dec 2021 → Jul 2022 | asthma | Dr. Grace Parraga | Withdrawn | No outcome recorded |
| Phase 3 | NCT02953379 | May → Dec 2019 | allergic rhinitis | EMS | Withdrawn | No outcome recorded |
| Phase 3 | NCT02953366 | May → Dec 2019 | allergic rhinitis | EMS | Withdrawn | No outcome recorded |
| Phase 3 | NCT03463031 | Mar → Nov 2018 | seasonal allergic rhinitis | Glenmark Specialty S.A. | Completed | No outcome recorded |
| Phase 3 | NCT03449836 | Mar → Sep 2018 | allergic disease | Federico II University | Unknown | No outcome recorded |
| Phase 3 | NCT03158311 | Feb 2018 → Jul 2019 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02709538 | Apr 2016 → Jul 2017 | perennial allergic rhinitis | Glenmark Specialty S.A. | Completed | No outcome recorded |
| Phase 3 | NCT02066298 | Jul 2014 → May 2018 | asthma | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01287364 | Feb → Apr 2011 | perennial allergic rhinitis | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01229085 | Sep 2006 → Oct 2007 | psoriasis | Azidus Brasil | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT03590912 | Sep 2018 → Feb 2020 | otitis media with effusion | Lumbini Medical College | Completed | No outcome recorded |
| Phase 4 | NCT03605537 | Jul 2018 → Oct 2019 | choanal atresia | Children's Hospital Medical Center, Cincinnati | Withdrawn | No outcome recorded |
| Phase 4 | NCT03011632 | Jan 2017 → Aug 2019 | asthma, chronic rhinosinusitis | Medical University of Lodz | Completed | No outcome recorded |
| Phase 4 | NCT00461812 | Apr 2007 → Jan 2010 | asthma | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 4 | NCT00783237 | Dec 2003 → Feb 2004 | allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00070707 | Apr → Nov 2003 | asthma, seasonal allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00763529 | Jan 2003 → Jan 2005 | psoriasis | Organon and Co | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02415179 | May 2015 → Feb 2016 | asthma | Mahidol University | Completed | No outcome recorded |
| — | NCT01210170 | Oct 2010 → Feb 2013 | asthma | University of Miami | Completed | No outcome recorded |
Also used as a comparator or background therapy in 23 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04615962 Comparator | Jan 2021 → Jan 2022 | atopic eczema | Seanergy Dermatology Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT01371786 Comparator | Jun → Aug 2011 | allergic rhinitis | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00721331 Comparator | Jul → Sep 2008 | atopic eczema | Zalicus | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03758950 Comparator | Nov 2018 → May 2023 | sickle cell disease | Jeffrey Glassberg | Completed | No outcome recorded |
| Phase 2 | NCT02318303 Comparator | Dec 2014 → Feb 2015 | seasonal allergic rhinitis | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 2 | NCT00941798 Comparator | Jul 2009 → May 2011 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00666679 Comparator | May 2008 → Feb 2009 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT05590598 Background | Feb → Jun 2023 | seasonal allergic rhinitis | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT04259164 Background | Sep 2020 → Dec 2022 | allergic asthma | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 3 | NCT03323866 Comparator | May 2017 → May 2022 | chronic rhinosinusitis | University of Sherbrooke | Terminated | No outcome recorded |
| Phase 3 | NCT02541760 Comparator | Apr 2014 → Mar 2015 | otitis media with effusion | Hormozgan University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01850823 Comparator | Feb → Dec 2013 | seasonal allergic rhinitis | Actavis Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01566149 Comparator | Mar → Sep 2012 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01401465 Comparator | Jul → Nov 2011 | perennial allergic rhinitis | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00562159 Background | Nov 2007 → Sep 2009 | allergic disease, conjunctivitis, rhinitis | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT07052942 Comparator | Aug 2025 → Nov 2029 expected | acute asthma | DARTNet Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT06272370 Comparator | Feb → Sep 2024 | asthma, hypersensitivity reaction disease, obstructive lung disease, respiratory tract infectious disorder | DARTNet Institute | Completed | No outcome recorded |
| Phase 4 | NCT05626621 Comparator | Nov 2022 → Aug 2025 overdue | chronic rhinitis | Endeavor Health | Recruiting | No outcome recorded |
| Phase 4 | NCT01676415 Comparator | Aug 2012 → Jan 2016 | chronic rhinosinusitis | Northwestern University | Terminated | No outcome recorded |
| Phase 4 | NCT01118312 Comparator | Sep 2010 → Jun 2014 | asthma, chronic rhinitis, sinusitis | JHSPH Center for Clinical Trials | Completed | No outcome recorded |
| Phase 4 | NCT00361439 Comparator | Aug 2006 → Sep 2008 | seasonal allergic rhinitis | University of Chicago | Terminated | No outcome recorded |
| Phase 4 | NCT00783458 Comparator | Dec 2004 → Jan 2005 | allergic rhinitis | Organon and Co | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06436534 Background | May 2024 → Oct 2026 expected | allergic rhinitis | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 60 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mometasone | “participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid...” NCT06272370 ↗54“Group 1 (n=236) will receive test product Azelastine + Mometasone, nasal spray, 140 mcg + 50 mcg/dose (Sandoz d.d., Slovenia), one actuation in each nostril twice daily,...” NCT05590598 ↗ “Background: Safety and efficacy of GSP301 nasal spray, an investigational fixed-dose combination of olopatadine hydrochloride and mometasone furoate, was established in three...” PMID 31248471 ↗ Jun 2019 “Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis,...” NCT00562159 ↗ “combination of mometasone furoate 0.1% and Salicylic Acid 5% in patients of both sexes who presented clinical symptoms of psoriasis of mild to moderate.” NCT01229085 ↗ “GSP301 nasal spray is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate.” PMID 35926824 ↗ Aug 2022 “Placebo to QVM149: 150 μg Indacaterol Acetate / 50 μg Glycopyrronium Bromide / 160 μg Mometasone Furoate od delivered via Breezhaler®” NCT05776927 ↗ “QVM149 is an investigational drug consisting of 150μg indacaterol acetate, 50μg glycopyrronium bromide and 160μg mometasone furoate.” NCT04206761 ↗ “a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy” NCT07052942 ↗ “QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device” NCT01636076 ↗ “665 μg of olopatadine and 25 μg of mometasone (twice-daily GSP301)” PMID 30321655 ↗ Oct 2018 “Indacaterol acetate / glycopyrronium bromide / mometasone furoate” NCT03158311 ↗ “QMF149 (Indacaterol Acetate / Mometasone Furoate)” NCT05562466 ↗ “Mometasone / Indacaterol” NCT04259164 ↗ “Mometasone Nasal Rinse” NCT05756647 ↗ |
| Known as | LAS 41002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01119313 ↗ |
| Known as | MFNS | “This study evaluates patient preference and satisfaction with ciclesonide hydrofluoroalkane nasal aerosol (CIC-HFA) compared with mometasone furoate aqueous nasal spray (MFNS).” PMID 24169063 ↗ Nov 20131“To evaluate the effectiveness of mometasone furoate nasal spray (MFNS) in subjects with seasonal allergic rhinitis (SAR).” PMID 16278257 ↗ Nov 2005 |
| Known as | Mometasone Furoate | “Background: Safety and efficacy of GSP301 nasal spray, an investigational fixed-dose combination of olopatadine hydrochloride and mometasone furoate, was established in three...” PMID 31248471 ↗ Jun 201910“GSP301 nasal spray is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate intended for seasonal allergic rhinitis...” PMID 30321655 ↗ Oct 2018 “This study evaluates patient preference and satisfaction with ciclesonide hydrofluoroalkane nasal aerosol (CIC-HFA) compared with mometasone furoate aqueous nasal spray (MFNS).” PMID 24169063 ↗ Nov 2013 “GSP301 nasal spray is a fixed-dose combination of the antihistamine olopatadine hydrochloride and the corticosteroid mometasone furoate.” PMID 35926824 ↗ Aug 2022 “fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol maleate and inhaled corticosteroid (ICS) mometasone furoate (MF)” PMID 25649209 ↗ Feb 2015 “Mometasone furoate 220mcg dry powder inhalation is a low-moderate ICS dose that can be given once daily.” NCT03758950 ↗ “QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device” NCT01636076 ↗ “Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge” NCT01061333 ↗ “One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray” NCT00783458 ↗ “Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI” NCT01566149 ↗ “mometasone furoate (corticosteroid)” PMID 31734334 ↗ Nov 2019 |
| Known as | Mometasone Furoate monohydrate | “Drug: Mometasone Furoate monohydrate” NCT01118312 ↗ |
| Known as | Mometasone Twisthaler | “Mometasone Twisthaler®, 400 µg QD” NCT00941798 ↗ |
| Modality | Other / unclassified | “Topical steroid medication” NCT01676415 ↗ |
| Route | Intranasal | “Mometasone nasal spray 200 mcg/day administered as 2 sprays (50 mcg/spray) in each nostril.” NCT00070707 ↗ |